tiprankstipranks
Repligen Reports Strong Q3 2024 with Revenue Growth
Company Announcements

Repligen Reports Strong Q3 2024 with Revenue Growth

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Repligen ( (RGEN) ) has provided an announcement.

Repligen Corporation reported a robust third quarter of 2024, with a 10% increase in revenue to $155 million year-over-year. The company experienced significant growth in the CDMO segment and equipment sales, each up by approximately 20%, and announced the acquisition of chromatography innovator Tantti Laboratory Inc. Repligen also opened a new Training and Innovation Center, enhancing its bioprocessing technology showcase. The adjusted net income reached $24 million, with a positive outlook for the upcoming year.

For detailed information about RGEN stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App